• EU regulators revoked the marketing authorization for TAVNEOS (avacopan), removing it from prescribing across the EU and EEA.
• The European Commission adopted the decision on Aug. 6, 2026, following an EMA CHMP recommendation dated June 26, 2026.
• The action followed an Article 20 non-pharmacovigilance review triggered by concerns over data handling in the Phase 3 ADVOCATE trial.
• CHMP concluded a positive benefit-risk balance could no longer be established, forcing a managed discontinuation with national authorities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSL Limited published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.